Nottingahshire apc
Nottinghamshire Area Prescribing Committee
  • Home
  • About
  • Shared Care
  • Guidelines/Formularies
    • Antimicrobial guidelines
  • JFG
    • Request a new medicine
  • Publications
    • Bulletins
    • Minutes of Meetings
    • Annual Reports
    • Stakeholder Survey
    • Publication Scheme
    • Privacy Policy
    • Website Disclaimer
    • Declarations of Interest
  • Links
  • Patient Info
  • De-prescribing/STOMP
  • COVID19
    • End of Life / Palliative Care (COVID)
    • COVID Treatment & Prevention
    • Respiratory
    • Anticoagulation & Haematology
    • Shared Care & High Risk Medicines
    • Prescribing - Clinical
    • Prescribing - Process
  • Home
  • COVID19
  • Shared Care & High Risk Medicines

Shared Care & High Risk Medicines - COVID FAQs

To ensure that you are seeing the most up to date information, refresh the page by pressing Ctrl and F5 together.

  • Valproate pregnancy prevention programme: temporary advice for management during COVID19 (MHRA)
  • Which patients on high risk medicines should shield / self-isolate during COVID19? (77 kb)
  • Should I stop DMARDs during COVID19? (117 kb)
  • DMARD monitoring during COVID19 (482 kb)
  • Riluzole (for MND) monitoring during COVID19 (422 kb)
  • Clozapine monitoring during COVID19 (299 kb)
  • Lithium monitoring during COVID 19 (522 kb)
  • Prescribing advice for patients with dermatological conditions prescribed immunosupressive medications (117 kb)
  • ADHD monitoring (children & young people) during COVID19 (375 kb)
  • Prescribing advice for patients with gastrointestinal and liver conditions treated with drugs affecting the immune response (426 kb)
  • Prescribing advice for patients with musculoskeletal and rheumatic conditions who require steroids (446 kb)
  • Managing chronic kidney disease (CKD) during COVID (473 kb)

Nottinghamshire Joint Formulary


© 2021 Nottinghamshire APC | Website Accessibility Statement